Cantor Fitzgerald Predicts Lower Earnings for MiMedx Group

MiMedx Group, Inc. (NASDAQ:MDXG) – Equities researchers at Cantor Fitzgerald dropped their FY2025 EPS estimates for MiMedx Group in a note issued to investors on Thursday, February 27th. Cantor Fitzgerald analyst R. Osborn now expects that the company will post earnings per share of $0.31 for the year, down from their previous forecast of $0.33. Cantor Fitzgerald has a “Overweight” rating and a $13.00 price objective on the stock. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.07. The business had revenue of $92.91 million for the quarter, compared to the consensus estimate of $89.42 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%.

Separately, StockNews.com downgraded shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday, November 8th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $12.00.

MiMedx Group Stock Performance

MDXG opened at $8.10 on Monday. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The company has a market cap of $1.19 billion, a price-to-earnings ratio of 14.73 and a beta of 1.94. MiMedx Group has a 52-week low of $5.47 and a 52-week high of $10.14. The firm’s fifty day simple moving average is $8.68 and its two-hundred day simple moving average is $7.75.

Institutional Investors Weigh In On MiMedx Group

A number of hedge funds have recently modified their holdings of the business. Paradigm Capital Management Inc. NY raised its position in shares of MiMedx Group by 0.5% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 4,686,231 shares of the company’s stock valued at $45,082,000 after buying an additional 22,131 shares during the last quarter. Cannell Capital LLC raised its position in shares of MiMedx Group by 1.1% in the fourth quarter. Cannell Capital LLC now owns 3,639,545 shares of the company’s stock valued at $35,012,000 after buying an additional 40,235 shares during the last quarter. First Light Asset Management LLC acquired a new stake in shares of MiMedx Group in the fourth quarter valued at about $32,168,000. Geode Capital Management LLC raised its position in shares of MiMedx Group by 1.6% in the third quarter. Geode Capital Management LLC now owns 2,794,358 shares of the company’s stock valued at $16,518,000 after buying an additional 44,254 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of MiMedx Group by 18.4% in the fourth quarter. Renaissance Technologies LLC now owns 1,804,557 shares of the company’s stock valued at $17,360,000 after buying an additional 280,327 shares during the last quarter. 79.15% of the stock is currently owned by institutional investors and hedge funds.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.